Duke doctor named new chair of NCCN board of directors
Thomas A. D’Amico, MD, has been elected chair of the board of directors of the National Comprehensive Cancer Network.
Thomas A. D'Amico, MD, has been elected chair of the board of directors of the National Comprehensive Cancer Network.
Dr. D'Amico is director of clinical oncology, program director of thoracic surgery, and professor in the department of surgery at Duke Comprehensive Cancer Center at Duke University in Durham, N.C.
His areas of expertise include the molecular biology of lung cancer, esophageal cancer, and also thoracic surgery. He is a member of several NCCN committees, and serves on the NCCN guidelines panel for esophageal/gastric cancers as well as on the panel for non-small-cell lung cancer.
Dr. D'Amico was previously vice-chair of the NCCN board and succeeds Al B. Benson III, MD, as chair.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
